Additional funding comprises €1.6 million in equity as well as a €1 million loan from Bpifrance PARIS, July 19, 2021 /PRNewswire/ -- PEP-Therapy, a biotechnology company developing cell penetrating ...

PARIS--PEP-Therapy, a biotechnology company developing targeted therapies for cancer treatments, has raised €1.3 million in initial funding. This sum, invested by the Quadrivium 1 seed fund and a ...

PEP-010, PEP-Therapy’s first-in-class bifunctional therapeutic peptide is being studied in an ongoing Phase Ib clinical trial evaluating safety, tolerability, pharmacokinetics and preliminary ...

PARIS, March 16, 2021 /PRNewswire/ -- PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and Institut Curie, France's leading cancer center, ...

Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer ...

French biotech Pep-Therapy SAS is in the midst of raising a €20 million (US$21.62 million) round and, at the same time, prospecting for potential partners after winning FDA orphan drug designation for ...

Smiths Medical, a leading medical device manufacturer, today announces the launch of the acapella (R) choice blue vibratory PEP therapy system. Acapella (R) is designed to aid in the removal of ...